Samantha Du, Ph.D.
Chief Scientific Officer and Executive Vice President, Chi-Med; and Chief Executive Officer, Hutchison MediPharma

Dr. Du joined Hutchison China in June 2001 as Senior Vice President and has since led all aspects of development and management of the company's R&D strategy. In 2002, she gained HWL's approval for the establishment of Hutchison MediPharma and has built up the company to over 70 employees. Dr. Du has led the advancement of two Phase II US clinical trials; the establishment of a rich discovery portfolio in less than three years; and establishment of strategic alliances with world leading research institutions and companies. Dr. Du is a well-recognised leader in the R&D arena in China through her advisory roles to various government bodies. Dr. Du started her research career at Pfizer's global R&D site in Connecticut, in the US, and led teams that delivered multiple INDs and NDAs for various anti-infective, cardiovascular, and metabolic medicines. Her last role at Pfizer was in the Global Strategic Operations Group, where she was in charge of licensing and related mergers and acquisitions activities in the metabolic disease area.

Dr. Du received her Ph.D. in Biochemistry from the University of Cincinnati, in the US, and her Bachelor's and Master's degrees in Molecular Biology and Chemistry from Jilin University, China.

Weiguo Su, Ph.D.
Senior Vice President, Drug Discovery
Hutchison MediPharma

Dr. Su joined Hutchison MediPharma in 2005, prior to which he spent fifteen years in Pfizer's US R&D organisation. Dr. Su delivered several high quality new drug candidates during his time with Pfizer with his last role being a director in the Medicinal Chemistry Department. He received his Ph.D. and post-doctoral fellowship in Chemistry from Harvard University under the guidance of Nobel Laureate Professor E. J. Corey and his Bachelor's degree in Chemistry from Fudan University in Shanghai, China.

Jimmy Wei, Ph.D., MBA
Vice President, Business Development
Hutchison MediPharma

Dr. Wei has over ten years of experience in the life sciences industry, in the areas of R&D, investment and business development. Dr. Wei is Vice President and head of the business development at Hutchison MediPharma. Previously, Dr. Wei was the Deputy General Manager of Burrill China Group, where he led Burrill’s business activities related to Greater China Area. Burrill is one of the largest life sciences VC fund with close to $1bln under management. Prior to joining Burrill, Dr. Wei worked for WI Harper Group (WIH) and oversaw its global life sciences investment. Before WIH, Dr. Wei was a management consultant at McKinsey Shanghai office. Dr. Wei has also conducted R&D in several leading research organizations, including Duke University Medical Center and Chinese Academia of Sciences. Dr. Wei has obtained a Ph.D. in Biochemistry from North Carolina State University. He also holds an M.B.A. from Darden Business School, University of Virginia.

Xun Zhang, Ph.D.
Vice President, Pharmaceutical Sciences & Project Operations, Hutchison MediPharma

Dr. Zhang joined Hutchison MediPharma in 2005, prior to which he spent eleven years in Pfizer's US R&D organisation where he was a director in the Pharmaceutical Sciences Division and, before that, four years at the Bristol-Myers-Squibb Research Institute. Dr. Zhang received his Ph.D. in Chemistry from the University of Texas at Austin and his Bachelor's degree in Chemistry from Peking University, China.

Xiaoqiang Yan, Ph.D.
Vice President, Research & Technology
Hutchison MediPharma

Dr. Yan joined Hutchison MediPharma in 2002, prior to which he spent over ten years in Amgen's US R&D organisation where he was a Molecular and Cell Biologist in haematology, pharmacology, pathology and functional genomics. Dr. Yan received his Ph.D. in Molecular and Cell Biology from the University of Toronto, Canada and his Bachelor's and Master's degrees in Medicine from the West China University of Sciences, China.

Zhenping Wu, Ph.D. MBA
Vice President, Pharmaceutical Sciences, Hutchison MediPharma

Dr. Wu joined Hutchison MediPharma in 2008 with 17 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. His past positions include Senior Director of Pharmaceutical Sciences at Phenomix Corporation, a California based drug discovery and development company, Director of Pharmaceutical Development at Pfizer Global Research & Development in San Diego, California (formerly Agouron Pharmaceuticals), and Senior Scientist at Roche Palo Alto site. Dr. Wu led many development project teams and advanced numerous drug candidates into different phases of clinical development and commercialization. The candidates include Sutent, a new blockbuster anti-cancer drug for Pfizer.

Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine. He is a past Chairman and President of the Board of Sino-American Biotechnology and Pharmaceutical Association. He received a Colleague Recognition Award from Pfizer in 2003 for his work on the Sutent project, a Dean's Scholar Award from the University of California at Irvine in the same year, and a Leadership Award from the Sino-American Biotechnology and Pharmaceutical Association in 2008. Dr. Wu was the recipient of an American Heart Association Fellowship in 1990.

Tom Tang, M.D., MBA
Vice President, Clinical and Regulatory Affairs
Hutchison MediPharma

Dr. Tang joined Hutchison MediPharma in 2007, prior to which he was a clinical program leader in Pliva Inc. and Pfizer/Pharmacia. Dr. Tang has more than 15 years experience in infectious diseases, immunology, endocrinology, and oncology. He received his Medical Degree from Capital University of Medicine in Beijing, China and his Master's degree in Business Administration from Rutgers University, the State University of New Jersey.